Drugs / GC1109
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01867957 | Feb → Dec 2009 | anthrax infection | Seoul National University Hospital | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT01624532 | Jul 2021 → Aug 2022 | anthrax infection | Green Cross Corporation | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GC1109 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01867957 ↗ |
| Modality | Vaccine | “The newly developed anthrax vaccine GC1109” NCT01867957 ↗ |
| Route | Intramuscular | “Administered in Multi Intramuscular Doses” NCT01624532 ↗ |